Profile data is unavailable for this security.
About the company
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-109.63m
- Incorporated2006
- Employees80.00
- LocationOlema Pharmaceuticals Inc780 Brannan StreetSAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 651-3316
- Fax+1 (302) 674-5266
- Websitehttps://olema.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stoke Therapeutics Inc | 15.16m | -103.57m | 723.91m | 110.00 | -- | 2.96 | -- | 47.76 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Savara Inc | 0.00 | -75.29m | 739.06m | 37.00 | -- | 6.10 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Annexon Inc | 0.00 | -115.16m | 742.75m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Replimune Group Inc | 0.00 | -220.01m | 745.39m | 331.00 | -- | 1.75 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Scholar Rock Holding Corp | 0.00 | -203.85m | 751.51m | 150.00 | -- | 5.62 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Zenas Biopharma Inc | 50.00m | -54.76m | 756.06m | 114.00 | -- | -- | -- | 15.12 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 758.90m | 73.00 | -- | 6.20 | -- | 75.43 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 763.18m | 586.00 | -- | 0.6870 | -- | 23.09 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Rapport Therapeutics Inc | -100.00bn | -100.00bn | 776.52m | 58.00 | -- | 2.30 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 781.11m | 80.00 | -- | 3.44 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 793.60m | 107.00 | -- | 2.52 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Erasca Inc | 0.00 | -158.28m | 816.44m | 126.00 | -- | 1.75 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 821.92m | 53.00 | -- | 2.29 | -- | 199.59 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 833.27m | 40.00 | -- | 2.80 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 30 Jun 2024 | 9.14m | 15.95% |
Paradigm BioCapital Advisors LPas of 01 Aug 2024 | 5.50m | 9.61% |
Deep Track Capital LPas of 30 Jun 2024 | 4.00m | 6.99% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.47m | 6.07% |
Point72 Asset Management LPas of 30 Jun 2024 | 3.21m | 5.61% |
Logos Global Management LPas of 30 Jun 2024 | 3.21m | 5.60% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 2.66m | 4.65% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.95m | 3.40% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.56m | 2.72% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.06m | 1.85% |